CorVel Corporation launches Marketwise Repricing™, enhancing medical bill management with market-based pricing solutions for cost containment.
Quiver AI Summary
CorVel Corporation has announced the launch of its new medical bill repricing solution, CorVel Marketwise Repricing™, aimed at improving cost containment in medical billing. This innovative approach integrates market-based reimbursement methods into CorVel's existing bill review processes, providing more accurate pricing that reflects local market conditions. Marketwise Repricing seeks to capture savings that traditional methods may overlook, making it particularly useful for out-of-network bills and in states with limited fee schedules. It is designed to enhance existing cost management strategies without adding administrative burdens. Key benefits include consistent pricing outcomes, improved cost containment, and seamless workflow integration, supported by real-world data.
Potential Positives
- Launch of CorVel Marketwise Repricing™, a market-based medical bill repricing solution, enhances cost containment for clients.
- Integration of market-based reimbursement methods into existing bill review workflows allows for capturing additional savings.
- Offers more consistent pricing outcomes that accurately reflect local market conditions, addressing the challenges of traditional billing methods.
- Seamless workflow integration provides end-to-end management, reducing administrative burdens for clients.
Potential Negatives
- Introduction of a new service like Marketwise Repricing may signal that existing solutions are not adequately addressing client needs, suggesting potential deficiencies in CorVel's previous offerings.
- The reliance on market-based reimbursement methods may expose the company to greater variability in pricing and potentially reduce predictability in financial forecasting.
- The forward-looking statements include disclaimers of potential risks and uncertainties, indicating that outcomes may not meet expectations, which could negatively impact investor confidence.
FAQ
What is CorVel Marketwise Repricing™?
CorVel Marketwise Repricing™ is a medical bill repricing solution that enhances cost containment through market-based reimbursement methods.
How does Marketwise Repricing improve cost containment?
The solution captures additional savings by integrating market-based intelligence within existing bill review workflows, reducing overall medical spend.
Who can benefit from Marketwise Repricing?
Employers, third-party administrators, insurance companies, and government agencies can benefit from the enhanced medical cost management it offers.
How does Marketwise Repricing work with existing billing strategies?
Marketwise Repricing complements existing network strategies, making it particularly useful for out-of-network bills and complex billing scenarios.
Where can I learn more about CorVel’s services?
To learn more about CorVel Marketwise Repricing™ and other services, visit www.corvel.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRVL Insider Trading Activity
$CRVL insiders have traded $CRVL stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $CRVL stock by insiders over the last 6 months:
- MICHAEL G COMBS (CEO & President) has made 0 purchases and 6 sales selling 36,513 shares for an estimated $2,164,393.
- STEVEN J HAMERSLAG has made 0 purchases and 2 sales selling 20,000 shares for an estimated $955,800.
- JEFFREY J MICHAEL sold 9,000 shares for an estimated $548,834
- MAXIM SHISHIN (Chief Information Officer) has made 0 purchases and 2 sales selling 4,650 shares for an estimated $265,931.
- JENNIFER YOSS (Vice President of Accounting) has made 0 purchases and 3 sales selling 1,999 shares for an estimated $121,979.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CRVL Revenue
$CRVL had revenues of $248.5M in Q4 2026. This is an increase of 7.36% from the same period in the prior year.
You can track CRVL financials on Quiver Quantitative's CRVL stock page.
You can access data on CRVL stock through the Quiver Quantitative API.
$CRVL Hedge Fund Activity
We have seen 158 institutional investors add shares of $CRVL stock to their portfolio, and 157 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OWLS NEST PARTNERS IA, LLC added 348,329 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,036,179
- THRIVENT FINANCIAL FOR LUTHERANS removed 287,218 shares (-93.2%) from their portfolio in Q1 2026, for an estimated $15,696,463
- PRICE T ROWE ASSOCIATES INC /MD/ removed 185,491 shares (-82.8%) from their portfolio in Q1 2026, for an estimated $10,137,083
- MORGAN STANLEY added 147,429 shares (+26.9%) to their portfolio in Q1 2026, for an estimated $8,056,994
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 141,313 shares (+24619.0%) to their portfolio in Q1 2026, for an estimated $7,722,755
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC removed 118,660 shares (-2.4%) from their portfolio in Q1 2026, for an estimated $6,484,769
- MARSHALL WACE, LLP added 114,015 shares (+228.3%) to their portfolio in Q1 2026, for an estimated $6,230,919
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
FORT WORTH, Texas, June 17, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (Nasdaq: CRVL), a national provider of risk management solutions, today announced the launch of CorVel Marketwise Repricing™, a market-based medical bill repricing solution designed to enhance cost containment while fitting seamlessly into existing bill review programs.
As medical billing continues to vary widely across states, providers, and care settings, traditional network and re-pricing approaches do not always reflect market pricing. Marketwise Repricing addresses this by integrating market-based reimbursement methods within CorVel’s existing bill review workflow. This approach captures additional savings that traditional bill review methods may miss, ultimately reducing overall medical spend.
“Marketwise Repricing gives clients a smarter, more supportable way to manage medical costs when traditional cost containment measures fall short,” said CJ Cypcar, Vice President, Network Solutions & Product Integration at CorVel. “It strengthens existing strategies by layering in market-based intelligence, without adding administrative burden.”
Marketwise Repricing uses real-world reimbursement data and market-based methods. This delivers more consistent pricing that better reflects local market conditions. It also works with existing network strategies, making it especially useful for out-of-network bills and in states with limited or no fee schedules.
Key benefits include:
- More consistent, supportable pricing outcomes across states and provider types
- Enhanced cost containment layered onto existing bill review programs
- An alternative methodology for complex or high-variance billing scenarios
- Seamless workflow integration, with end-to-end management by CorVel
To learn more about CorVel Marketwise Repricing™ and CorVel’s bill review solutions, visit www.corvel.com .
About CorVel
CorVel Corp. applies technology, including artificial intelligence, machine learning, and natural language processing, to enhance the management of episodes of care and related health care costs. We partner with employers, third-party administrators, insurance companies, and government agencies in managing workers’ compensation and health, auto, and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel’s customized services, delivered locally, are backed by a national team to support our partners and their customers and patients.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates and projections about the Company, management’s beliefs, and certain assumptions made by the Company, and events beyond the Company’s control, all of which are subject to change. Such forward-looking statements include, but are not limited to, statements relating to the Company’s services and the Company’s continued investment in these and other innovative technologies, and statements relating to the Company’s product offerings. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially and adversely from those expressed in any forward-looking statement results of operations and financial condition is greater than our initial assessment. The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company’s filings with the Securities and Exchange Commission, including but not limited to “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarters ended June, 30, 2025, September 30, 2025 and December 31, 2025. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.
Contact: Melissa Storan
Phone: 949-851-1473
www.corvel.com
